Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China

Phase 3

Completed

Conditions: Opiate Dependence
HIV Infections

Interventions: Behavioral: Drug counseling
Behavioral: Behavioral Drug and HIV Risk Reduction Counseling (BDRC)

First Posted Date: 2008-09-23

Last Posted Date: 2020-03-30

Lead Sponsor: Yale University

Target Recruit Count: 45

Registration Number: NCT00757744

Locations: 🇺🇸
Yale University School of Medicine - CMHC, New Haven, Connecticut, United States
🇨🇳
Wuhan Center for Disease Control and Prevention, Wuhan, Hubei, China

Compromised Microcirculation in Women With Polycystic Ovary Syndrome

Early Phase 1

Completed

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: ganirelix acetate
Drug: methyl testosterone

First Posted Date: 2008-09-23

Last Posted Date: 2016-07-04

Lead Sponsor: Yale University

Target Recruit Count: 28

Registration Number: NCT00757185

Locations: 🇺🇸
John B. Pierce Laboratory, New Haven, Connecticut, United States

Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)

Not Applicable

Completed

Conditions: Vitamin D Deficiency
Polycystic Ovarian Syndrome

Interventions: Dietary Supplement: Vitamin D2 (Ergocalciferol)
Drug: Medroxyprogesterone (Provera)
Dietary Supplement: Vitamin D3 (Cholecalciferol)
Dietary Supplement: Elemental Calcium

First Posted Date: 2008-08-29

Last Posted Date: 2021-08-13

Lead Sponsor: Yale University

Target Recruit Count: 36

Registration Number: NCT00743574

Locations: 🇺🇸
Yale-New Haven Hospital-Women's Center, New Haven, Connecticut, United States

Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).

Phase 3

Completed

Conditions: Alcohol Dependence
Stress Disorders, Post-Traumatic

Interventions: Drug: Prazosin
Drug: Placebo

First Posted Date: 2008-08-29

Last Posted Date: 2020-03-19

Lead Sponsor: Yale University

Target Recruit Count: 96

Registration Number: NCT00744055

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

Not Applicable

Terminated

Conditions: Gastrointestinal Carcinoid Tumor
Islet Cell Tumor
Metastatic Cancer

Interventions: Drug: PVA microporous hydrospheres/doxorubicin hydrochloride

First Posted Date: 2008-08-08

Last Posted Date: 2017-08-25

Lead Sponsor: Yale University

Target Recruit Count: 13

Registration Number: NCT00730483

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Chronic Pain and Opioid Dependence Assessment and Treatment

Not Applicable

Completed

Conditions: Chronic Pain
Opioid Dependency

Interventions: Behavioral: Integrated Cognitive Behavioral Therapy

First Posted Date: 2008-08-04

Last Posted Date: 2020-04-03

Lead Sponsor: Yale University

Target Recruit Count: 15

Registration Number: NCT00727675

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

A Double-blind Study to Determine if Intraduodenal Indomethacin Can Decrease the Incidence of Post-ERCP Pancreatitis

Not Applicable

Completed

Conditions: Pancreatitis

Interventions: Drug: Placebo suspension
Drug: Indomethacin

First Posted Date: 2008-08-04

Last Posted Date: 2017-01-18

Lead Sponsor: Yale University

Target Recruit Count: 117

Registration Number: NCT00727740

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer

Phase 1

Completed

Conditions: Advanced Breast Cancer

Interventions: Drug: Vorinostat

First Posted Date: 2008-07-22

Last Posted Date: 2017-03-03

Lead Sponsor: Yale University

Target Recruit Count: 24

Registration Number: NCT00719875

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Pregnancy in Polycystic Ovary Syndrome II

Phase 3

Completed

Conditions: Polycystic Ovary Syndrome
Pregnancy

Interventions: Drug: Clomiphene citrate
Drug: Letrozole

First Posted Date: 2008-07-21

Last Posted Date: 2018-06-14

Lead Sponsor: Yale University

Target Recruit Count: 750

Registration Number: NCT00719186

Locations: 🇺🇸
Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States
🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
Yale University, New Haven, Connecticut, United States

and more 9 locations

The Effect of Protein on Calcium Absorption and Gastric Acid Production

Phase 4

Completed

Conditions: Osteoporosis

Interventions: Drug: esomeprazole
Drug: Placebo

First Posted Date: 2008-07-21

Last Posted Date: 2020-03-06

Lead Sponsor: Yale University

Target Recruit Count: 12

Registration Number: NCT00719160

Locations: 🇺🇸
Yale New Haven Hospital Hospital Research Unit, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy